

March 8, 2018 Wealth Research

Q3FY18 Result Update

Ahluwalia Contracts (India) Ltd

Good quarter, order book execution – key to growth

Accumulate

In-line

Ahluwalia Contracts (India) Ltd (ACIL), for Q3FY18, reported decent numbers. Revenue grew by ~1% YoY to ₹361 crore, growth was muted on the back of GST impact (adjusting for the same, revenue would have been up by 9-10%). Execution of better margin orders led to EBITDA margin expansion of 413bps to 17.3%. Good operational performance aided net profit growth of 20% to ₹29 crore. As of 31 Dec′17 debt was at ₹61 crore (vs ₹63 crore as of 30 Sept′17).

Management Guidance: For FY18, the management has maintained revenue growth guidance of 15-20%, EBITDA margin guidance to 13-14%. It expects order inflows worth ₹1,300 crore in FY18 and ₹1,600 crore in FY19.

Recommendation: Post our Q2FY18 result update *click here* (21 Nov'17 @ ₹358, Rating: Accumulate), ACIL touched its 52 week high of ₹426 (on 27 Dec'17). The stock has corrected to ₹371 levels (return ~4% since the update) and trades at a P/E of 16.6/14.1x on FY19E/20E basis. ACIL's cautious bidding approach and execution of better margin orders has enabled EBITDA margin expansion for the quarter. Owing to the competitive intensity being high we have maintained our EBITDA margin estimates of ~13% over FY18-20. The company has a healthy bid pipeline and its focus on higher ticket size projects (+₹500 crore) could aid future growth. We maintain our Accumulate rating and value the company at 16x FY20E EPS giving a target price of ₹421.

Q3FY18 Result Summary

	· /				
Y/E Mar (₹ Cr.)	Q3FY18	Q3FY17	YoY (%)	Q2FY18	QoQ (%)
Revenue	361	358	0.8	335	7.9
EBITDA	62	47	32.4	50	25.4
Margin (%)	17.3	13.2	413bps	14.9	240bps
PAT	29	24	19.5	26	13.2
EPS (₹)	4.35	3.64		3.85	

Source: Company, Centrum Wealth Research

Focus on high margin orders — to augur well: So far during FY18, ACIL has received orders worth ₹1,260 crore, taking the order book to ₹3,575 crore (as of 31 Dec'17). Over the last few months competitive intensity has been high owing to regional players coming in. ACIL has thus adopted a cautious bidding approach in order to safe guard margins and is now looking at higher ticket size orders (where competition is low at present). Given the opportunities and competitive intensity, we expect the company to maintain margin of ~13% over FY18E-20E.

Good balance sheet position: As of 31 Dec'17 debt stands at ₹61 crore. We anticipate ACIL to be a debt free company by FY20E. We believe for now the company would not be requiring any major capex (~₹20 crore − regular capex estimated), however the same could differ owing to the requirements of any big ticket orders. We expect lower capex requirement and better order execution to generate healthy cash flows which could aid debt reduction and improve the working capital cycle. In addition, the company has some assets in the real estate segment which it would look to monetise once the market stabilizes.

Risk factors: 1) Any adverse news on the CBI investigation case could result in stock price correction, 2) Prolonged increase in sub-contracting expenses to hurt margins, 3) Delay in payments, leading to higher working capital requirement.

Key Data Current Market Price (₹) 371 Target Price (₹) 421 Potential upside 13.7% Sector Relative to Market In-line

Stock Information

BSE Code	532811
NSE Code	AHLUCONT
Face Value (₹/Share)	2.0
No. of shares (Cr.)	6.7
Market Cap (₹ Cr.)	2,482
Free float (₹ Cr.)	1,043
52 Week H / L (₹)	426/236
Avg. Daily turnover (12M, ₹ Cr.)	1.8

Shareholding Pattern (%)

	Dec-17	Dec-16
Promoters#	58.0	62.4
Mutual Funds	14.3	14.8
FPIs	20.1	15.8
Others including Public	7.6	7.0

#Promoter holding diluted post sale of shares by promoter member in Apr'17.

1 year Indexed Price Performance



Price Performance (%)

	1M	3M	6M	1YR
ACIL	8.5	2.9	33.6	21.9
S&P BSE Small Cap	(4.7)	(5.2)	5.8	26.7

Source: Bloomberg, Centrum Wealth Research


Mrinalini Chetty, Research Analyst

Financial Summary

Y/E Mar (₹ Cr.)	Revenue	YoY (%)	EBITDA	EBITDA (%)	NPAT	YoY (%)	EPS (₹)	P/E (x)	EV/EBITDA (x)	RoE (%)
FY16A	1,250	17.9	161	12.9	84	31.8	12.60	29.4	15.7	22.2
FY17A	1,427	14.2	173	12.1	86	1.9	12.84	28.9	14.2	18.5
FY18E	1,684	18.0	219	13.0	119	37.9	17.70	20.9	11.0	21.2
FY19E	1,909	13.4	256	13.4	149	25.9	22.29	16.6	9.0	22.0
FY20E	2,153	12.8	291	13.5	176	18.1	26.32	14.1	7.5	21.4

Source: Company, Centrum Wealth Research

Exhibit 1: Order Book as of 31 Dec'17 (₹3,575 crore)



Source: Company, Centrum Wealth Research

Q3FY18 Concall Highlights

- ➤ Current order book of ₹3,575 crore is to be executed over 2.5 years. Over the long term, the company targets to keep the public and private order book mix to 50:50. Slow moving orders at ₹200 crore.
- Currently working at 40 project sites (has capacity to handle 50 projects at once).
- Project Bid Pipeline At present stands at ₹2,500 crore, 80% of which is from Government NBCC, CPWD, HSCC, it also includes Private orders from existing clients Brookfield, Emaar MGF. The company is looking at bidding for airport projects along with JV partners (as it does not qualify on a standalone basis as they are higher ticket size projects of ₹1,000 crore). The management stated that it is witnessing some traction in the commercial arena and also in the realty space.
- > The competition intensity for project bidding has increased on the back of regional players coming in. In some projects the company has witnessed qualification criteria (technical and net worth) being diluted and hence has adopted a cautious bidding approach. The management expects the same to stabilize in the months to come.
- Interest cost during the quarter were high owing to a one-time provision of ₹8 crore (on account of DVAT liability). Average cost of debt at present stands at 9-9.5%.
- ➤ Kota Project 9MFY18 revenue ₹85 lakh, Accounting loss ₹8 crore, Cash loss ₹1.44 crore.

Exhibit 2: Quarterly Performance

Y/E Mar (₹ Cr.)	Q3FY17	Q4FY17	Q1FY18	Q2FY18	Q3FY18
Revenue	358	472	504	335	361
YoY Growth %	11.9	23.0	64.6	15.2	0.8
Raw Materials	189	250	275	118	146
% of sales	52.7	53.0	54.5	35.1	40.5
Personnel Expenses	37	33	32	34	34
% of sales	10.4	7.0	6.3	10.2	9.5
Other Expenses	85	145	144	133	118
% of sales	23.7	30.8	28.5	39.8	32.7
EBIDTA	47	43	54	50	62
EBIDTA margin %	13.2	9.1	10.6	14.9	17.3
Depreciation	6.1	6.7	6.3	6.4	6.4
Interest	6.0	7.3	3.8	4.6	12.4
Other Income	1.2	2.1	1.5	1.0	1.1
PBT	36.3	31.2	45.0	39.8	44.8
Provision for tax	11.9	10.9	15.4	14.1	15.6
Effective tax rate %	32.7	34.8	34.3	35.3	34.9
Net Profit	24.4	20.4	29.5	25.8	29.2
YoY Growth %	23.0	(23.8)	35.3	29.0	19.6
PAT margin %	6.8	4.3	5.9	7.7	8.1

Source: Company, Centrum Wealth Research

From the Technical & Derivative Desk

- After a strident rally in 2014, the stock has started moving in the sideways direction.
- > The consolidation phase of last three years has resulted into formation of a 'Rising Channel' on weekly chart.
- > The stock is currently hovering around the upper end of the mentioned channel and forming a 'Triple Top' pattern on weekly chart.
- > The 'RSI' oscillator too has given a negative divergence on weekly chart; indicating limited upside in the counter.
- > Considering above technical evidence, we may see a corrective move in the stock towards 310 320 levels in coming weeks. ON the flipside strong resistance is placed around 425 level.

Exhibit 3: Technical Chart



Source: Company, Centrum Wealth Research

Financials

Income Statement

Y/E Mar (₹ Cr)	FY16	FY17	FY18E	FY19E	FY20E
Revenue	1,250	1,427	1,684	1,909	2,153
Growth %	17.9	14.2	18.0	13.4	12.8
Raw Materials	607	726	839	951	1,072
% of sales	48.6	50.9	49.8	49.8	49.8
Personnel Expenses	159	154	150	170	192
% of sales	12.7	10.8	8.9	8.9	8.9
Other Expenses	323	374	477	533	599
% of sales	25.8	26.2	28.3	27.9	27.8
EBIDTA	161	173	219	256	291
EBIDTA margin %	12.9	12.1	13.0	13.4	13.5
Depreciation	20	24	26	27	28
Interest	35	27	21	10	3
Other Income	14	8	8	8	8
PBT	119	131	180	226	267
Provision for tax	35	45	61	77	91
Effective tax rate %	29.2	34.1	34.0	34.0	34.0
Net Profit	84	86	119	149	176
Growth %	31.8	1.9	37.9	25.9	18.1
PAT margin %	6.8	6.0	7.0	7.8	8.2

Source: Company, Centrum Wealth Research

Balance Sheet

Y/E Mar (₹ Cr)	FY16	FY17	FY18E	FY19E	FY20E
Share capital	13	13	13	13	13
Reserves & surplus	409	495	598	731	892
Shareholder's fund	422	508	611	745	906
Loan fund	133	90	60	25	0
Total cap. employed	555	598	671	770	906
Net fixed assets	197	193	187	180	172
Deferred Tax Assets	15	13	13	13	13
Investments	6	6	6	6	6
Cash and bank	88	123	144	201	298
Inventories	205	201	281	314	354
Debtors	557	602	761	863	973
Loans & adv and OCA	89	98	135	153	172
Total current assets	939	1,023	1,322	1,531	1,797
Current lia. and prov.	602	637	857	961	1,083
Net current assets	337	386	464	570	714
Total assets	555	598	671	770	906

Source: Company, Centrum Wealth Research. OCA – Other Current Assets

Cash Flow

Y/E Mar (₹ Cr)	FY16	FY17	FY18E	FY19E	FY20E
Net Profit Before Tax	119	131	180	226	267
Depreciation	20	24	26	27	28
Others	17	16	13	2.6	(4.6)
Change in working capital	(72)	(31)	(57)	(49)	(48)
Tax expenses	(7)	(12)	(61)	(77)	(91)
Cash flow from Ops	77	127	101	130	152
Capex	(22)	(20)	(20)	(20)	(20)
Other investing activities	(3)	11	8	8	8
Cash flow from Invest	(25)	(9)	(12)	(12)	(12)
Proceeds from equity	-	-	-	-	-
Borrowings/(Repayments)	(31)	(52)	(30)	(35)	(25)
Dividend paid	-	-	(16)	(16)	(16)
Interest paid	(26)	(19)	(21)	(10)	(3)
Cash flow from financing	(58)	(71)	(67)	(61)	(44)
Net Cash Flow	(6)	48	22	57	96

Source: Company, Centrum Wealth Research

Key Ratios

key katios					
Y/E Mar	FY16	FY17	FY18E	FY19E	FY20E
Return ratios (%)					
RoE	22.2	18.5	21.2	22.0	21.4
RoCE	29.5	27.3	31.6	32.8	32.2
Turnover Ratios (days)					
Inventory	54	52	52	57	57
Debtors	152	148	148	155	156
Creditors	82	83	86	89	89
Fixed asset turnover (x)	3.6	3.6	3.6	4.0	4.3
Solvency Ratio (x)					
Debt-Equity	0.3	0.2	0.1	0.0	0.0
Interest coverage	4.4	5.9	9.6	23.2	90.1
Per share (₹)					
EPS	12.6	12.8	17.7	22.3	26.3
BVPS	63.0	75.9	91.2	111.2	135.2
CEPS	15.6	16.4	21.6	26.3	30.5
Dividend Ratios					
DPS (₹)	-	-	2.0	2.0	2.0
Dividend Yield (%)	-	-	0.5	0.5	0.5
Dividend Payout (%)	-	-	13.1	10.4	8.8
Valuation (x)					
P/E	29.4	28.9	20.9	16.6	14.1
P/BV	5.9	4.9	4.1	3.3	2.7
EV/EBIDTA	15.7	14.2	11.0	9.0	7.5
EV/Sales	2.0	1.7	1.4	1.2	1.0

Source: Company, Centrum Wealth Research

Appendix

Disclaimer

Centrum Broking Limited ("CBL") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE), National Stock Exchange of India Ltd. (NSE) and MCX-SX Stock Exchange Limited (MCX-SX). One of our group companies, Centrum Capital Ltd is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. CBL or its affiliates do not own 1% or more in the equity of this company Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of CBL. CBL and its affiliates do not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of CBL. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, CBL, Centrum group, the authors of this report of the projections and forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. We do not provide tax advice to our clients, and all investors are strongly advised to consult regarding any potential investment. CBL and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by CBL, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. CBL has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of CBL. This report or any portion hereof may not be printed, sold or distributed without the written consent of CBL.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither CBL nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the fore going limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of CBL and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

CBL and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. CBL and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by his/her, research analyst and the author of this report and/or any of his/her family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by his/her, he/she has not received any compensation from the above companies in the preceding twelve months. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavor to update the information herein on a reasonable basis, CBL, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where CBL is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Disclosures under the SEBI (Research Analysts) Regulations 2014

	Disclosure of Interest Statement					
1	Limited (CRL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.				
2	I Details of Disciplinary History of CRI	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.				
3	Registration status of CBL	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)				

4	Whether Research analysts or relatives' have any financial interest in the subject company and nature of such financial interest	No
5	Whether Research analysts or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6	Whether the research analysts or his relatives has any other material conflict of interest	No
7	Whether research analysts have received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8	Whether the Research Analysts have received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No
10	Whether the Research Analysts has been engaged in market making activity of the subject company.	No

Member (and BSE)

Regn No.:

CAPITAL MARKET SEBI REGN. NO.: BSE: INB011454239
CAPITAL MARKET SEBI REGN. NO.: NSE: INB231454233
DERIVATIVES SEBI REGN. NO.: NSE: INF231454233
(TRADING & CLEARING MEMBER)
CURRENCY DERIVATIVES: MCX-SX INE261454230
CURRENCY DERIVATIVES:NSE (TM & SCM) – NSE 231454233

Depository Participant (DP)

CDSL DP ID: 120 – 12200 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Website: www.centrum.co.in
Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Kavita Ravichandran (022) 4215 9842; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN: U67120MH1994PLC078125) Corporate Office & Correspondence Address REGD. OFFICE Address Bombay Mutual Bldg., 2nd Floor, 2nd Floor, Dr. D.N. Road, Fort, Mumbai - 400 001 Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E) Mumbai 400 098. Tel: (022) 4215 9000 Fax: +91 22 4215 9344